A federal appeals court in the US has ruled in favour of three pharma companies in a dispute over the supply of discounted medicines to contract pharmacies with the Health
Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Bi
Biogen has cut the list price of its Alzheimer's disease therapy in half from $56,000 to $28,200 a year, before the outcome of an ongoing reimbursement review of the drug by the US governme
Under fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have reached an agreement that could see the policy reintroduced in the Biden administr
A jury in the US has charged a Florida man who owns multiple telemedicine companies in connection with a massive healthcare scam that involved a massive $784 million in fraudulent claims be
The US government has started a review of how Biogen and Eisai's pricey new Alzheimer's disease therapy Aduhelm will be covered by Medicare, to see if a national strategy needs to be adopte
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.